Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade

Immune checkpoint inhibitors target the inhibitory receptors on T cells to reinstate their antitumor ability and have shown significant efficacy in treating various cancers. However, because of tumor heterogeneity and many other uncover reasons, the objective response rate for programmed death 1 and...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2020-03, Vol.11, p.339
Main Authors: Jiang, Youhai, Zhao, Xiaofang, Fu, Jing, Wang, Hongyang
Format: Article
Language:English
Subjects:
B7-H1 Antigen - analysis
Combined Modality Therapy
Gastrointestinal Microbiome
Humans
Immune Checkpoint Inhibitors - adverse effects
Immune Checkpoint Inhibitors - therapeutic use
Immunology
immunotherapy
Mutation
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - immunology
Obesity - complications
patient response
PD-1
PD-L1
precise treatment
Programmed Cell Death 1 Receptor - analysis
Tumor Microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors target the inhibitory receptors on T cells to reinstate their antitumor ability and have shown significant efficacy in treating various cancers. However, because of tumor heterogeneity and many other uncover reasons, the objective response rate for programmed death 1 and programmed death-ligand 1 (PD-1/PD-L1) blockade is only 20 to 30%; its response rate in solid tumors is relatively low, and different degrees of side effects have occurred. There are still many unknown factors affecting the therapeutic effectiveness of PD-1/PD-L1 blockade. Additionally, screening the responding tumor patients accurately and improving the response rate and efficacy are huge challenges for tumor precise treatment. Here, we attempt to summarize the recent progress in response prediction and combined application of PD-1/PD-L1 blockade and briefly discuss the methods and evaluations combined with PD-1/PD-L1 blockade to improve the implementation of precision immunotherapy.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2020.00339